EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Serum Proteomic Profile Based on the TGF‐β Pathway Stratifies Risk of Hepatocellular Carcinoma

Xiyan Xiang, Kirti Shetty, Herbert Yu, Bibhuti Mishra, Linda L Wong, Xianghong Jasmine Zhou, Sanjaya K Satapathy, James M Crawford iD, Patricia S Latham, Steven-Huy Han, Brandon Mathew, Nabil N Dagher und 8 weitere

Liver International · 2025

DOI: 10.1111/liv.70325 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Liver International, 2025. Verfasst von Xiyan Xiang und 19 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Department of Medicine, The Institute for Bioelectronic Medicine, Feinstein Institutes for Medical Resea…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Liver Cirrhosis, Transforming Growth Factor beta. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NIAAA NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hepatocellular carcinoma (HCC) is the third leading cause of cancer‐related deaths, primarily due to late‐stage diagnosis. In this multicenter study, our goal is to identify functional biomarkers that stratify the risk of HCC in patients with cirrhosis (CP) for early diagnosis.

Methods

Five thousand and eight serum proteins (Somascan) were analysed in Cohort A (477 CP, including 125 HCC). Clustering analysis of the TGF‐β pathway‐associated protein signature was performed in a longitudinal, prospective Cohort B (312 CP, in which 18 cases developed HCC over a 5‐year follow‐up period). Next, a multivariable prediction model was built using logistic regression analysis of cross‐sectional data from a matched subgroup ( n = 328, Cohort C). Model performance was 10‐fold cross‐validated across the entire Cohort A ( n = 477).

Results

Longitudinal follow‐up analysis revealed that patients with elevated TGF‐β‐related protein signature displayed a five‐fold increased risk of developing HCC (9.68% vs. 1.91%). Compared to cirrhosis, serum MSTN, TGFBR2, and AFP levels raised in HCC were validated by ELISA ( n = 200, odds ratio = 1.4–2.9, p < 0.05). In Cohort C, 88 proteins were significantly altered in HCC compared to cirrhosis ( p < 0.05). The six‐protein panel (TGFBR2, MSTN, AFP, COL18A1, GLUL, TP63) displayed a strong performance in the matched cohort C (AUC 0.87, sensitivity 0.88, specificity 0.72), alongside four clinical factors (Age, Sex, BMI, Bilirubin). A 10‐fold cross‐validation demonstrated a mean AUC of 0.86 in cohort A, with strong predictive power in obese/MASLD/ALD‐related patients (AUCs: 0.862–0.921).

Conclusions

The mechanism‐based panel effectively stratifies HCC risk in cirrhotic patients, underscoring the need for Phase II/III validation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsLiver CirrhosisTransforming Growth Factor betaBiomarkers, TumorHumansMaleFemaleMiddle AgedProteomicsProspective StudiesAgedLongitudinal StudiesLogistic ModelsCross-Sectional StudiesRisk AssessmentRisk FactorsReceptor, Transforming Growth Factor-beta Type II

Stichwörter der Autor:innen

cirrhosisearly diagnosisliver cancerproteomicssurveillance

Substanzen

Transforming Growth Factor betaBiomarkers, TumorReceptor, Transforming Growth Factor-beta Type II

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, Department of Medicine, The Institute for Bioelectronic Medicine, Feinstein Institutes for Medical Research & Cold Spring Harbor Laboratory, Northwell Health, Manhasset, New…
  • Division of Gastroenterology and Hepatology, Department of Medicine, The University of Maryland, School of Medicine, Baltimore, Maryland, USA.
  • Department of Epidemiology, The University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
  • Department of Surgery, University of Hawaii, Honolulu, Hawaii, USA.
  • Department of Pathology and Laboratory Medicine, Ronald Reagan Medical Center, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.
  • Division of Hepatology, Northwell Health, and Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York, USA.

ORCID-Profile: James M Crawford

Förderung

  • NCI NIH HHS
  • NIAAA NIH HHS
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Xiang, X., Shetty, K., Yu, H., Mishra, B., Wong, L. L., Zhou, X. J., Satapathy, S. K., Crawford, J. M., Latham, P. S., Han, S. H., Mathew, B., Dagher, N. N., Lau, L., Cacaj, F., Vegesna, A. K., Dasarathy, S., He, A. R., Huang, H., Amdur, R. L., & Mishra, L. (2025). Serum Proteomic Profile Based on the TGF‐β Pathway Stratifies Risk of Hepatocellular Carcinoma. Liver International. https://doi.org/10.1111/liv.70325

Vancouver

Xiang X, Shetty K, Yu H, Mishra B, Wong LL, Zhou XJ, et al. Serum Proteomic Profile Based on the TGF‐β Pathway Stratifies Risk of Hepatocellular Carcinoma. Liver International. 2025. doi:10.1111/liv.70325

BibTeX
@article{Xiang2025,
  author = {Xiang, Xiyan and Shetty, Kirti and Yu, Herbert and Mishra, Bibhuti and Wong, Linda L and Zhou, Xianghong Jasmine and Satapathy, Sanjaya K and Crawford, James M and Latham, Patricia S and Han, Steven-Huy and Mathew, Brandon and Dagher, Nabil N and Lau, Lawrence and Cacaj, Fellanza and Vegesna, Anil K and Dasarathy, Srinivasan and He, Aiwu R and Huang, Hai and Amdur, Richard L and Mishra, Lopa},
  title = {Serum Proteomic Profile Based on the TGF‐β Pathway Stratifies Risk of Hepatocellular Carcinoma},
  journal = {Liver International},
  year = {2025},
  doi = {10.1111/liv.70325}
}
Kostenlos starten →